Assertio Holdings, Inc.
NASDAQ:ASRTDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $151.86M
- Beta
- 0.53
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$5.55
Volume 0.27M
Average 0.33M
ASRT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Assertio Holdings, Inc.NASDAQ: ASRT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $5.84M fell 37.0% year over year, behind the -9.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.
Context
- Depreciation & amortization amounted to 25.3% of revenue in FY2025, up 4.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -37.0% toward the trailing-twelve-month pace of -9.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 30.01M USD
- Year-over-year change
- +16.2%
- 4-year CAGR
- +0.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.01M | +16.2% |
| FY2024 | 2024-12-31 | 25.83M | -8.5% |
| FY2023 | 2023-12-31 | 28.23M | -15.5% |
| FY2022 | 2022-12-31 | 33.4M | +14.7% |
| FY2021 | 2021-12-31 | 29.11M | — |
Depreciation & Amortization vs competitors
How ASRT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.6% is the 3rd highest of 10, against a peer median of -18.4%.
- Depreciation & amortization amounts to 26.0% of revenue for ASRT, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.58M USD | -9.6% | -3.5% | 26.0% | |
| LTM Jun 2025 | ₪12.91M ILS | +61.3% | +13.6% | 5.3% | |
| LTM Mar 2026 | $7.46M USD | -16.4% | +13.9% | 2.9% | |
| LTM Mar 2026 | $5.17M USD | -29.3% | -20.7% | 7.8% | |
| LTM Mar 2026 | $2.88M USD | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M USD | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.39M USD | +27.4% | +55.0% | — |
| LTM Mar 2026 | $996K USD | -37.8% | -11.4% | 1.1% | |
| LTM Apr 2026 | $170.49K USD | -37.6% | -19.3% | 9.5% | |
| LTM Mar 2026 | $130K USD | -84.1% | -41.1% | — | |
| Peer median (excluding ASRT) | — | -18.4% | -13.6% | 6.6% | |
Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 111.01M | 156.23M | 152.07M | 124.96M | 118.71M |
| Cost of Revenue | 15.83M | 18.75M | 27.02M | 39.23M | 65.39M |
| Gross Profit | 95.18M | 137.49M | 125.05M | 85.73M | 53.33M |
| Gross Margin | 85.7% | 88.0% | 82.2% | 68.6% | 44.9% |
| Research & Development | 0 | 0 | 2.84M | 3.82M | 1.69M |
| Selling, General & Admin | 56.56M | 48.1M | 69.74M | 76.95M | 68.86M |
| Operating Expenses | 85.76M | 98.08M | 368.59M | 110.21M | 70.55M |
| Depreciation & Amortization | 29.11M | 33.4M | 28.23M | 25.83M | 30.01M |
| EBITDA | 38.78M | 90.17M | 53.17M | 5.15M | 3.14M |
| EBITDA Margin | 34.9% | 57.7% | 35.0% | 4.1% | 2.6% |
| Operating Income | 9.42M | 39.41M | (243.54M) | (24.48M) | (17.22M) |
| Operating Margin | 8.5% | 25.2% | -160.1% | -19.6% | -14.5% |
| Interest Income | 0 | 0 | 0 | 3.22M | 2.67M |
| Interest Expense | 10.22M | 7.96M | 3.38M | 3.04M | 3.08M |
| Other Income / Expenses | (9.98M) | (8.24M) | (10.52M) | 2.95M | (12.72M) |
| Income Before Tax | (553K) | 31.17M | (254.05M) | (21.53M) | (29.94M) |
| Pre-Tax Margin | -0.5% | 19.9% | -167.1% | -17.2% | -25.2% |
| Income Tax Expense | 728K | (78.46M) | 77.89M | 52K | 435K |
| Net Income | (1.28M) | 109.63M | (331.94M) | (21.58M) | (30.38M) |
| Net Margin | -1.2% | 70.2% | -218.3% | -17.3% | -25.6% |
| EPS (Basic) | (0.45) | 34.95 | (70.05) | (3.45) | (4.74) |
| EPS (Diluted) | (0.45) | 30.45 | (70.05) | (3.45) | (4.74) |
| Weighted Avg Shares | 2.88M | 3.13M | 4.74M | 6.35M | 6.4M |
| Weighted Avg Shares (Diluted) | 2.88M | 3.64M | 4.74M | 6.35M | 6.4M |
Assertio Holdings, Inc.
NASDAQ:ASRT
Intrinsic Alpha fair value
Locked
Current Price
$23.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.